Recommended Antibiotics for MRSA Cellulitis
For MRSA cellulitis, the first-line treatment options are trimethoprim-sulfamethoxazole (TMP-SMX), linezolid, clindamycin (if susceptibility is confirmed), or daptomycin, with the choice depending on severity and patient factors. 1
Treatment Algorithm Based on Severity
Uncomplicated MRSA Cellulitis (Outpatient)
First-line options:
Duration: 5-10 days, extending if infection has not improved within 5 days 1
Complicated MRSA Cellulitis (Requiring Hospitalization)
First-line options:
Duration: 10-14 days, may extend to 21 days for severe infections 1, 2
Special Considerations
Antibiotic Selection Factors
- TMP-SMX: Excellent MRSA coverage but limited activity against β-hemolytic streptococci 1
- Clindamycin: Requires confirmed susceptibility; monitor for C. difficile infection 1
- Linezolid: Preferred for MRSA pneumonia; excellent oral bioavailability 2, 3
- Daptomycin: Preferred for MRSA bacteremia/endocarditis; not effective for pneumonia 4, 5
Adjunctive Measures
- Incision and drainage is essential if there is a purulent collection 1
- Ensure wounds are covered with clean, dry bandages 1
- Maintain good personal hygiene to prevent infection spread 1
Dosing Considerations
Weight-based dosing is critical:
- Clindamycin: ≥10 mg/kg/day
- TMP-SMX: ≥5 mg TMP/kg/day
- Inadequate dosing is associated with clinical failure 1
Vancomycin dosing should target trough concentrations of 15-20 mg/L for severe infections 6
- Standard dosing of 1g IV every 12 hours often fails to achieve therapeutic levels 6
Emerging Treatment Options
- Combination therapy with daptomycin plus ceftaroline has shown promising results in recent research for MRSA bacteremia, with potentially reduced mortality compared to monotherapy 7
Common Pitfalls to Avoid
- Underdosing antibiotics, particularly in obese patients
- Failing to obtain susceptibility testing before using clindamycin
- Not performing incision and drainage when indicated
- Discontinuing antibiotics prematurely before complete resolution
- Using daptomycin for pulmonary infections (inactivated by lung surfactant)